Tuesday, the FDA said it would convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee on Monday, June 10, 2024, to discuss Eli Lilly and Co’s LLY donanemab ...

May 6, 2024 Enanta Pharmaceuticals, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third ...

According to Lilly, donanemab slowed Alzheimer’s disease progression by 35 percent relative to placebo treatment, in an ...

The phase 2B, multicenter, double-blind, placebo-controlled, dose-optimization study of MM120 enrolled 198 adults with moderate to severe GAD (mean baseline HAM-A scores of approximately 30). They ...

Calliditas Therapeutics had a typical to-do list for its midphase head and neck cancer study. Step one, show the molecule shrinks tumors. | Calliditas Therapeutics had a typical to-do list for its ...

A supplement formulated with American ginseng, Brahmi, and coffee fruit extract could improve mood and working memory, ...

Early research suggests setanaxib combined with pembrolizumab may be a promising treatment for patients with squamous cell carcinoma of the head and neck.

Data on several novel injectable drugs were presented at the World Congress on Osteoarthritis, as well as updated data on the gene therapy XT-150.

An experimental anti-nicotine drug appears to help people quit vaping, a new study says. Cytisinicline is a naturally occurring plant-based substance that binds to nicotine receptors in the brain, ...

(RTTNews) - NeuroSense Therapeutics (NRSN) announced new analyses from Phase 2b PARADIGM clinical trial, demonstrated a statistically significant slowing of disease progression in high-risk ALS ...

Lumateperone given as adjunctive therapy to antidepressants met the primary endpoint by demonstrating reduction in the Montgomery Asberg Depression Rating Scale (MADRS) total score compared to placebo ...

Madrigal also expects to reinforce Rezdiffra’s clinical profile—and potentially convert the current accelerated approval to a full nod—with patient outcomes data from the MAESTRO-NASH trial. That ...